BD Names Christopher DelOrefice as EVP and CFO

BD (Becton, Dickinson and Company), a global medical technology company, has announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept. 6, 2021. DelOrefice succeeds Christopher Reidy, 64, who announced his intent to retire from BD last week.
 
DelOrefice, 50, will join BD from Johnson & Johnson (J&J), where he is currently vice president of Investor Relations. In nearly two decades at J&J, DelOrefice has also held a variety of senior finance leadership roles, including CFO of both the Consumer and Medical Devices segments for North America. He also held finance leadership roles for J&J Supply Chain, Corporate Mergers and Acquisitions, Consumer Global R&D and the Pharmaceutical North America Business Development and Commercial Contracting Finance groups. Prior to J&J, DelOrefice held leadership positions in cost accounting, global audit and financial reporting at Astra Zeneca Pharmaceuticals, AET Films, Inc. and Ametek, Inc.
 
“Chris has the right mix of strong operational and corporate finance experience that is highly relevant to his new role as CFO at BD,” said Tom Polen, chairman, CEO and president of BD. “His deep experience in health care and medical technology — including supporting multiple large businesses and functions at J&J — will help create a seamless transition as CFO. His investor relations expertise provides additional value to the investment community who know him well. Chris’ track record leading and developing strong finance teams will be an asset to BD.”
 
DelOrefice will gain immediate responsibility of the global finance organization when joining BD, and Reidy will transition the leadership of BD’s Technology & Global Services (TGS) organization to DelOrefice by the end of the calendar year.
 
“It is an exciting time to be joining BD as it continues to evolve into one of the most relevant global medical technology companies in the world,” said DelOrefice. “The positive impact on the lives of patients worldwide and its ability to make meaningful progress on some of the most challenging global health issues of our time make BD truly unique in the medical technology industry. I look forward to helping the BD team drive its 2025 growth strategy, optimize its margins and continue to generate shareholder value.”
 
DelOrefice earned his Bachelor of Science and Master of Business Administration degrees from Villanova University. He received his certified public accountant certification from the Commonwealth of Pennsylvania. He is a member of the Global Investor Relations Executive Council and also remains actively engaged in education and development initiatives at Villanova University.